"Win-win cooperation and mutual benefit" is the concept of development and cooperation that Umibio (Shanghai) Co., Ltd. has been adhering to. Recently, under the efforts of both sides, Umibio (Shanghai) Co., Ltd. and Resun (Shenzhen) Technology Co., Ltd. formally reached a strategic cooperative partnership!
Myasthenia gravis (MG) is an autoimmune disease caused by the dysfunction of nerve-muscle junction transmission. The clinical manifestations are mainly partial or systemic skeletal muscle weakness and fatigue. The prevalence rate is (77~150)/1 million, and the annual incidence rate is (4~11)/1 million. Recently, research from Zhao Chongbo and Luo Sushan’s team in Huashan Hospital of Fudan University found out that low-dose rituximab (RTX) is effective in the treatment of patients with acetylcholine receptor (AChR) positive refractory myasthenia gravis. Meanwhile, RTX can reduce the level of serum exosome miR-150. The results suggest that exosome miR-150 is a potential biomarker for myasthenia gravis disease.
The project High-throughput and Ultrasensitive Biological Detection Platform Based on Nanopore Technology submitted by Resun (Shenzhen) Technology Co., Ltd. won the first class funding of Pre-employment Expenses of Overseas Students in Shenzhen in 2020.
